Quick Jump Command Palette

↑ ↓ Navigate ↵ Open compound + Compare Pin to compare ESC Dismiss

Side-by-Side Analytical & Price Matrix

Compound Comparison

Analytical specificity and contaminant screening

Chromatographic purity does not constitute a toxicological safety profile.

In analytical peptide biochemistry, chromatographic purity is routinely conflated with biological safety. Empirical forensic testing of gray-market peptide supply chains reveals a consistent pattern: nominal product labeling frequently diverges from true vial composition, and non-target impurities remain uncharacterized.

The reporting

Forensic analysis of secondary market formulations

In August 2026, the Australian Broadcasting Corporation (ABC) published analytical findings examining counterfeit and gray-market formulations of investigational multi-receptor peptides distributed via online storefronts, after reported cases of acute liver injury tied to those vials:

Quantitative variance
Of eighteen independent samples subjected to quantitative assay, only one conformed to its nominal label strength. The remaining seventeen demonstrated significant over- or under-concentration.
Compositional discrepancy
Target peptide mass accounted for approximately 10% of total solids in evaluated vials; the remaining 90% comprised uncharacterized secondary compounds and excipients.
Documented harm
The reporting described severe acute liver injury, including cases that reached transplant.
Investigational status
Investigational multi-receptor peptides remain unapproved chemical compounds without global marketing authorization. Consequently, any retail formulation sold as a finished product for personal use is unapproved and unvalidated by definition.
Methodological limits

What identity and purity assays do not tell you

Standard commercial Certificates of Analysis generally report results from two analytical methodologies: reverse-phase high-performance liquid chromatography (RP-HPLC) for relative peak area integration, and electrospray ionization mass spectrometry (ESI-MS) for molecular mass verification.

Analytical chemist loading an unlabeled lyophilized peptide vial into a numbered HPLC autosampler rack
Baseline Chromatographic Assay (RP-HPLC & ESI-MS). Confirms retention-window elution and target mass-to-charge ratio on the tested aliquot.
Laboratory counter with six unlabeled green-capped vials, nitrile glove, and analytical notes
Orthogonal Receiving Screening. Non-chromophoric impurities, endotoxins, heavy metals, and residual solvents require dedicated secondary assays at intake.

“All that they know from this testing is that there is some target peptide in their vials. It doesn’t actually tell them if there’s any other contaminants or any other drugs or medications that could be mixed with them.”

Dr Marie Sinclair, transplant hepatologist, Austin Health, quoted by the ABC

“We had two different laboratories help us with that and did a very extensive analysis of components in these vials, and even with extensive testing we don’t have the full picture.”

Dr Marie Sinclair, on forensic screening of vials associated with acute toxicity

Optical RP-HPLC coupled with single-quadrupole ESI-MS remains blind to:

Bacterial endotoxins
Pyrogenic lipopolysaccharides (LPS) requiring specialized Limulus amebocyte lysate (LAL) or recombinant Factor C (rFC) fluorometric assays.
Heavy metal catalysts
Residual palladium, tin, or lead scavengers undetectable without inductively coupled plasma mass spectrometry (ICP-MS).
Residual synthesis reagents
Trace organic solvents (e.g., trifluoroacetic acid, dichloromethane, dimethylformamide, piperidine) requiring headspace gas chromatography-mass spectrometry (GC-MS).
Microbial and fungal bioburden
Viable particulate contamination undetectable without specialized compendial sterility cultures.
Institutional quality control

Scope of supplier analytical documentation

Lyotide Scientific provides batch-specific manufacturer CoAs to supply empirical baseline documentation for intake logging. This documentation does not confer a safety certification, nor does it clear material for in vivo applications.

Certificate of analysis
Empirical evidence of compound identity and relative optical purity for an individual manufacturing batch, derived under specified conditions at a specific time point.
Exclusions
A standard CoA is not a toxicological evaluation, sterility certification, endotoxin clearance, or validation for in vivo veterinary or human use.
Commercial positioning
We supply institutional and commercial enterprises strictly under a for research and development / laboratory use only (RUO) mandate.
Internal release
Enterprise clients are expected to subject all inbound raw materials to internal orthogonal analytical verification aligned with their specific experimental tolerances.

Related reading: research-use boundary, compounding regulatory landscape, and evaluating a peptide COA.

Carbonell, R., Gribbin, C., & Yu, A. (2026, August 28). ABC News (Australia). Read the original report. Quotations are the ABC’s; the commentary is ours.